ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AGIO Agios Pharmaceuticals Inc

31.49
-0.20 (-0.63%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agios Pharmaceuticals Inc NASDAQ:AGIO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -0.63% 31.49 19.80 34.10 32.01 31.31 31.70 419,310 01:00:00

Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019

04/03/2019 12:00pm

GlobeNewswire Inc.


Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Agios Pharmaceuticals Charts.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Cowen 39th Annual Health Care Conference in Boston on Monday, March 11, 2019 at 12:00 p.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About AgiosAgios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

Investor & Media Contact:Holly Manning, 617-844-6630Associate Director, Investor RelationsHolly.Manning@agios.com

1 Year Agios Pharmaceuticals Chart

1 Year Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock